Physician profile
Jordan Bruce Pritikin
NPI 1770585259
$167,132.30
in general payments reported to CMS, 2019-2025
27 companies · $6,901 in 2025
The $6,901 reported for 2025 was more than what 96% of Plastic Surgery Within The Head & Neck providers received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $19K · 2021: $25K · 2022: $29K · 2023: $27K · 2024: $36K · 2025: $6,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $9,468 · Travel and Lodging: $3,262 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,105.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,340.00 |
| Food and Beverage | $9,467.51 |
| Travel and Lodging | $3,262.22 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $109,546.70 | 2019-2025 | |
| Optinose US, INC. | $42,055.57 | 2019-2025 | |
| Olympus America INC. | $5,622.27 | 2021-2022 | |
| Genzyme Corporation | $1,912.40 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,754.65 | 2019-2025 | Dupixent |
| Alk-Abello, INC | $1,266.32 | 2019-2025 | Odactra, Ragwitek, Grastek |
| Intersect Ent, INC. | $950.14 | 2019-2022 | |
| Glaxosmithkline, LLC. | $773.31 | 2019-2025 | Nucala |
| Gyrus Acmi, INC. | $690.00 | 2022 | |
| Spirair, INC. | $464.96 | 2024-2025 | Septalign |
| Medtronic, INC. | $431.89 | 2023-2025 | Nuvent, N/A, Sinuva |
| Stryker Corporation | $377.38 | 2019-2023 | Xpress Ent Dilation System |
| Astrazeneca Pharmaceuticals Lp | $373.12 | 2019-2025 | Tezspire |
| Inspire Medical Systems, INC. | $250.09 | 2022 | |
| Apyx Medical Corporation | $138.71 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $117.53 | 2025 | |
| Neurent Medical Limited | $93.31 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 | |
| Paratek Pharmaceuticals, INC. | $64.78 | 2025 | Xhance |
| Acclarent, INC | $41.13 | 2019 | |
| Hikma Pharmaceuticals USA | $28.00 | 2024-2025 | Ryaltris |
| Amgen INC. | $25.00 | 2022 | |
| Phadia US INC. | $25.00 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $23.23 | 2025 | Neffy |
| Greer Laboratories, INC. | $19.31 | 2019 | |
| Merck Sharp & Dohme LLC | $12.75 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Pritikin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.